The immune response triggered by UB-312, an experimental vaccine by Vaxxinity, effectively targeted alpha-synuclein protein aggregates and slowed their toxic buildup in the cerebrospinal fluid (CSF) of Parkinson’s disease patients in a Phase 1 trial, compared with those given a placebo, data show. The full target engagement triggered…
News
A sensor chip that can distinguish harmless single units of proteins tied to diseases like Parkinson’s from those whose toxic aggregates are thought to drive disease — including alpha-synuclein — could help in diagnosing conditions before symptoms are evident, when treatments can work best, a study suggests. In addition…
Among available dopamine agonists to treat early Parkinson’s disease, ropinirole is the least likely to cause dyskinesia, the  involuntary movements that can occur from long-term use of these and other Parkinson’s medications, a meta-analysis study suggests. Pramipexole, meanwhile, may be the least likely to cause wearing off…
Scientists have shown that co-transplanting stem cells with regulatory T-cells — immune cells known as Tregs that dampen excessive inflammatory and immune responses — can boost cell survival in the brain in rodent models of Parkinson’s disease, and also ease motor symptoms. These findings propose a new strategy…
Participating in a group singing program can help with speaking ability and emotional well-being for people with Parkinson’s disease, as well as foster better relationships between patients and their spouses, a new study highlights. “Our findings extend previous research on group singing in PD [Parkinson’s disease] by looking in…
Gaps in healthcare for individuals with Parkinson’s disease in the U.S. have been identified, with notable disparities observed for women, individuals belonging to minority groups, and residents living in rural areas. That’s according to a study utilizing 2019 Medicare data, which includes approximately 90% of individuals living with Parkinson’s…
NodThera’s NT-0796, an investigational oral therapy for Parkinson’s disease, reduced several inflammatory markers in elderly volunteers in seven days, according to initial data from a Phase Ib/IIa study. Parkinson’s patients are now being recruited for the trial’s second phase to determine the therapy’s impact on a panel of clinical…
Gb Sciences has completed a study testing its experimental cannabinoid-based therapy for Parkinson’s disease in rodents. The study, which was conducted at the University of Lethbridge, in Canada, tested a range of doses of the investigational therapy, establishing how long it takes each dose to have an effect…
Internalized, experienced, or anticipated stigma have significant impacts on employment experiences for people with Parkinson’s disease, according to a recent study. In semi-structured interviews with patients, a researcher identified that patients felt hesitant to disclose their diagnosis in the workplace or ask for disability-related accommodations, often due to a…
Higher levodopa doses were associated with a drop in blood pressure among older Parkinson’s patients, those with 65 or more years, in the early and middle stages of the disease, a study reported. Cognitive impairment was identified as a risk factor for a sudden blood pressure drop when…
Recent Posts
- Looking back at the changing roles and relationships in Parkinson’s
- Lab-made small molecule may help slow brain disease progression
- New report shows Parkinson’s costs surpass $82 billion in US in 2024
- Pushing forward this Parkinson’s Awareness Month with boldness, grace
- Personalized DBS for Parkinson’s may result from brain study in China